These findings further demonstrate the significant role of mucin-type O-glycosylation in modulating cancer malignancy and suggest that C1GALT1 may be a promising therapeutic candidate that targets multiple signaling pathways in HCC. This evidence concerns the gene C1GALT1 and hepatocellular carcinoma.